Compare · BGLC vs MOH
BGLC vs MOH
Side-by-side comparison of BioNexus Gene Lab Corp (BGLC) and Molina Healthcare Inc (MOH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BGLC and MOH operate in Medical Specialities (Health Care), so they compete in similar markets.
- MOH carries a market cap of $16.65B.
- Over the past year, BGLC is down 17.9% and MOH is down 45.1% - BGLC leads by 27.2 points.
- MOH has been more active in the news (3 items in the past 4 weeks vs 1 for BGLC).
- MOH has more recent analyst coverage (25 ratings vs 0 for BGLC).
- Company
- BioNexus Gene Lab Corp
- Molina Healthcare Inc
- Price
- $2.31-10.47%
- $175.91+0.84%
- Market cap
- -
- $16.65B
- 1M return
- -10.47%
- +25.82%
- 1Y return
- -17.94%
- -45.10%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2003
- News (4w)
- 1
- 3
- Recent ratings
- 0
- 25
Molina Healthcare Inc
Molina Healthcare, Inc. provides managed health care services to low-income families and individuals under the Medicaid and Medicare programs and through the state insurance marketplaces. The company operates in two segments, Health Plans and Other. As of December 31, 2020, it served approximately 4.0 million members eligible for Medicaid, Medicare, and other government-sponsored healthcare programs in 15 states. The company offers its health care services for its members through contracts with a network of providers, including independent physicians and physician groups, hospitals, ancillary providers, and pharmacies. Molina Healthcare, Inc. was founded in 1980 and is headquartered in Long Beach, California.
Latest BGLC
- SEC Form 10-K filed by BioNexus Gene Lab Corp
- SEC Form NT 10-K filed by BioNexus Gene Lab Corp
- BioNexus Gene Lab Corp filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard™ MRD Platform
- BioNexus Gene Lab Corp filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman
- BioNexus Gene Lab Corp filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- BioNexus Launches Regional Deployment of VitaGuard™ MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ASEAN's Multi-Billion Dollar Market
- BioNexus Gene Lab Corp filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- BioNexus Gene Lab Corp filed SEC Form 8-K: Other Events
Latest MOH
- SEC Form 10-Q filed by Molina Healthcare Inc
- Molina Healthcare Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Molina Healthcare Reports First Quarter 2026 Financial Results
- SEC Form 4 filed by Grohowski Leo P
- SEC Form 4 filed by Lockhart Stephen H
- SEC Form 4 filed by Orlando Steven J
- SEC Form 4 filed by Wolf Dale B
- SEC Form 4 filed by Zoretic Richard C
- SEC Form 4 filed by Schapiro Richard M
- SEC Form 4 filed by Brasier Barbara L